Daiichi Sankyo Co., Ltd: PharmaVitae Profile
Datamonitor, December 2010, Pages: 59
Introduction
This analysis examines the historical and forecast performance for Daiichi Sankyo in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Daiichi Sankyo's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
- Strategic insight into the prospects for Daiichi Sankyo over the next six years.
- Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Daiichi Sankyo's performance against key rivals in the prescription pharmaceutical sector
- Identify the key growth drivers that will propel Daiichi Sankyo to the second biggest company in the Japan pharma peer set in terms of Rx sales
- Look at the strategies being employed by Daiichi as it looks to outperform its Japanese peers
Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–
Financial performance, 2003–
Daiichi Sankyo: PharmaVitae forecasts at a glance
Strategic insight
Successful prevention of generic threat
Ranbaxy acquisition to drive growth over 2009–
Daiichi Sankyo has the strongest launch/core/expiry outlook in the Japan pharma peer set
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest comment
[Missing title]
Latest prescription pharma news
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
M&A history
[Missing title]
Current corporate structure
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–
Product analysis
Product analysis, 2003–
Product analysis, 2009–
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-
Core analysis, 2009-
Expiry analysis, 2009-
Generics analysis, 2009-
Launch/core/expiry configuration, 2009–
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Operating costs and profit analysis
Operating costs and profit analysis, 2003–
Operating cost ratio and profit margin analysis, 2003–
Operating cost ratio and profit margin analysis, 2009–
Operating costs and profit analysis, 2009–
APPENDIX
Abbreviations
Exchange rates
ACS Motion Control Ltd
Astellas Pharma
AstraZeneca PLC
Automatic Data Processing, Inc.
Bristol-Myers Squibb Company
Chugai Pharmaceutical Co. Ltd
CuraGen Corporation
Daiichi Sankyo, Ltd.
Dainippon Sumitomo Pharma Co., Ltd.
Eli Lilly and Company
Forest Laboratories, Inc
IMS Health
Merck & Co., Inc.
Novartis AG
Pfizer Inc
Santen Pharmaceutical Co., Ltd.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
